{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fiambio.simplecast.com%2Fepisodes%2Fhow-biotechs-survive-the-valley-of-death-redux-vtI4wmB6","width":444,"version":"1.0","type":"rich","title":"How Biotechs Survive the Valley of Death (REDUX)","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/9b3967de-d938-42f2-b54e-99b29c007c9b/edf95499-0c7d-4519-8809-c86b3b8795c1/bio-podcast-logo-1.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/b1b921db-2fb2-4d0d-a095-ebbf9fb14928\" height=\"200\" width=\"100%\" title=\"How Biotechs Survive the Valley of Death (REDUX)\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. \n"}